The AMA released a series of codes that would be eligible for reporting a COVID-19 vaccine under development by Novavax Inc.
While the Novavax vaccine has yet to gain clearance from the U.S. Food and Drug Administration, the Gaithersburg, Md.-based biotechnology company has accelerated its testing and development and plans to ship hundreds of millions of products to the European Union later in the year.
Like other vaccine developers, the company also is expanding its testing of the vaccine to younger age groups, including children between the ages of 12 to 17.
The AMA code update, which includes two immunization codes and two administration codes for the pending Novavax product, joins a roster of five total vaccine codes and follows the previously approved codes in sequential order. Here’s the full descriptor of the Category I CPT code:
- 91304 (Severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease (COVID-19)] vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use).
The code would cover the first and second doses of the Novavax vaccine. The AMA code release also contains two administration codes:
- 0041A (Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease (COVID-19)] vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose).
- 0042A (Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease (COVID-19)] vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose).
References:
1 thought on “AMA issues codes for pending Novavax vaccine: COVID update”